PLoS Medicine Vol. 6 no. 10 (2009) e1000165
В настоящем документе представлен первоначальный обзор поступающей информации
(по состоянию на 2 июля 2020 г.) о взаимосвязи между COVID-19, НИЗ и факторами
риска НИЗ. Ре...цензируемые статьи взяты из баз данных NCBI PubMed, PMC и Google
Scholar. Данный обзор свидетельствует о том, что лица, живущие с НИЗ, подвержены
более высокому риску развития тяжелого заболевания и смерти в связи с COVID-19,
и об ограниченности данных для оценки риска. Наряду с этим в нем обобщаются
результаты двух проведенных ВОЗ обследований, указывающих на то, что с началом
пандемии была серьезно нарушена система предоставления услуг по профилактике и
лечению НИЗ.
Response to non-communicable diseases during and after the COVID-19 pandemic
more
The new Global AIDS Strategy 2021--2026, End Inequalities, End AIDS, is a bold approach that uses an inequalities lens to close the gaps preventing progress to end AIDS
Available in: English, French, Chinese, Spanish, Russian, Arabic, Thai, Korean, Tajik, Vietnamese, Uzbek
http://www.who.int/disabilities/cbr/guidelines/en/
Available in: English, French, Chinese, Spanish, Russian, Arabic, Thai, Korean, Tajik, Vietnamese, Uzbek
http://www.who.int/disabilities/cbr/guidelines/en/
NFPA continues to work with partners to respond to the Ukraine emergency. Highlights from the month of January include:
- The #TrainOfHope launched between Kyiv and Chisinau is a lifeline, providing refugees, including many women with children, both a route to safety and a way back home.
- When t...he Government of Ukraine lost control of Kherson city, social workers at a shelter for survivors of domestic violence continued to work so that women and girls could receive essential assistance.
more
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
Infectious Diseases of Poverty 2014, 3:42
http://www.idpjournal.com/content/3/1/42
Capability and Performance
Midnight, Executive Director
midnightp@apcom.org
Accessed: 27.08.2019
https://doi.org/10.1016/j.vaccine.2019.09.099
Our analysis included 14 Asian countries that were estimated to have a total of 850,000 choleracases and 25,500 deaths in 2015 While, the WHO cholera report documented around 60,000 cholera casesand 28 deaths. We estimated around $20.2 million (I$74.4 m...illion) in out-of-pocket expenditures, $8.5million (I$30.1 million) in public sector costs, and $12.1 million (I$43.7 million) in lost productivity in2015. Lost productivity due to premature deaths was estimated to be $985.7 million (I$3,638.6 million).Our scenario analyses excluding mortality costs showed that the economic burden ranged from 20.3%($8.3 million) to 139.3% ($57.1 million) in high and low scenarios when compared to the base case sce-nario ($41 million) and was least at 10.1% ($4.1 million) when estimated based on cholera cases reportedto WHO
more